← Back to headlines
Kailera Stock Falls Following Late-Stage Trial Data for GLP-1 Candidate
Kailera's shares experienced a decline after the release of late-stage trial data for its oral GLP-1 candidate. The specific details of the trial data and the extent of the stock drop were not immediately clear.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
